Data from Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers
Husain Yar Khan(Wayne State University), Asfar S. Azmi(The Barbara Ann Karmanos Cancer Institute), Philip A. Philip(Wayne State University), Sahar F. Bannoura(The Barbara Ann Karmanos Cancer Institute), Hirva Mamdani(Wayne State University), Amro Aboukameel(The Barbara Ann Karmanos Cancer Institute), Mohammed Najeeb Al Hallak(The Barbara Ann Karmanos Cancer Institute), Yosef Landesman(Karyopharm Therapeutics (United States)), Misako Nagasaka(University of California, Irvine), Md. Hafiz Uddin(Wayne State University), Anthony F. Shields(Wayne State University), Yousef Mzannar(The Barbara Ann Karmanos Cancer Institute), Dipesh Uprety(The Barbara Ann Karmanos Cancer Institute), Steve Kim(The Barbara Ann Karmanos Cancer Institute), Yiwei Li(Ningxia Medical University), Rafic Beydoun(The Barbara Ann Karmanos Cancer Institute), Rachel Sexton(The Barbara Ann Karmanos Cancer Institute), Ramzi M. Mohammad(The Barbara Ann Karmanos Cancer Institute)
Cited by 0
Related Papers
Recommendations on the Use of <sup>18</sup>F-FDG PET in Oncology
|Journal of Nuclear Medicine|2008|1.1k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
|Journal of Clinical Oncology|2020|391
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
|Frontiers in Immunology|2022|373